Weighing Long-Term Survival and Quality of Life With Atezolizumab Plus Bevacizumab

The panel discusses long-term survival and quality of life with atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC). Team Chicago Hot Dog acknowledges that IMbrave150 lacks the mature, landmark survival data now available for tremelimumab plus durvalumab, prompting a conversation about where median overall survival falls relative to the tail of the curve. The experts agree that patient selection is critical, noting that the robust response rates with atezolizumab plus bevacizumab make it attractive for patients with bulky tumor burden who need rapid disease control. Several panelists emphasize that most patients with advanced HCC are treated with palliative intent, making quality of life and tolerability central considerations. They highlight the convenience of every-four-week durvalumab dosing and the reassurance provided by 5-year survival and ALBI-stratified data. The discussion underscores balancing depth and durability of response against treatment burden when selecting frontline immunotherapy regimens for individual patients with advanced HCC.